The global computational pathology market size is expected to reach USD 1,447.62 million by 2033, registering a CAGR of 9.0% from 2025 to 2033, according to a new report by Grand View Research, Inc. This growth can be attributed to the rising prevalence of chronic diseases, the increasing demand for advanced solutions for faster diagnosis, the rising integration of Machine Learning (ML) and artificial intelligence (AI) technologies and increasing investment in healthcare supported by market players focused on developing advanced solutions.
Integrating artificial intelligence (AI) and machine learning (ML) algorithms into digital pathology workflows is revolutionizing the field, enabling faster and more accurate analysis of pathology images. AI-powered tools can assist pathologists in detecting patterns, predicting disease progression, and giving clinically relevant insights crucial for disease detection. For instance, In September 2024, Paige introduced Paige Alba, a clinical-grade multimodal co-pilot aimed at transforming personalized medicine and precision oncology. Alba provides real-time, AI-driven insights from patient data, enhancing clinical decision-making at unprecedented speed and scale. This innovation represents a major leap toward Artificial General Intelligence (AGI) in healthcare, bringing the industry closer to a future where AI not only supports but collaborates with clinicians in diagnosing and treating complex diseases such as cancer.
Several companies operating in the market also focusing on developing innovative solutions to enhance the application and performance of computational pathology. For instance, in August 2023, Microsoft and Paige researchers developed Virchow2 and Virchow2G, second-generation foundation models for computational pathology. These large language models are trained on vast amounts of pathology data to understand the complex relationships between clinical information, pathology findings, and disease outcomes.
Virchow2 and Virchow2G can generate human-readable text, answer questions, and assist in tasks like report generation and case summarization. The models are designed to be fine-tuned for specific tasks, enabling their use in various computational pathology applications. This advancement represents a significant step forward in leveraging AI to enhance pathologists’ decision-making and improve patient care in computational pathology. Similarly, transitioning from traditional microscopy to digital pathology further contributes to the market growth. This shift enhances accessibility and facilitates remote consultations and collaborative efforts among pathologists worldwide.
The COVID-19 pandemic has accelerated this trend as healthcare systems search for alternatives to execute operations while ensuring compliance with safety protocols. Furthermore, regulatory bodies significantly contribute to digital pathology’s growth, leading to approvals for various digital imaging systems and software applications. As organizations invest in infrastructure to support digital workflows, the market is expected to witness significant growth driven by enhanced operational efficiencies and improved diagnostic capabilities.
Request a free sample copy or view report summary:
Computational Pathology Market Report
Based on component, software segment dominated the market in 2024 owing to the various advantages offered by these solutions that help in enhancing clinical workflows.
Based on application disease diagnosis dominated the application segment with a revenue share of 46.2% in 2024 owing to the rising demand for more effective and accurate diagnosis tools in hospitals and diagnostics centers globally.
Based on technology, machine learning dominated the market in 2024 owing to the rising development of computational pathology solutions with integrated ML technologies that offer better performance and outcomes in healthcare facilities.
Based on end use, hospitals and diagnostic labs segment held the largest market share of 51.09% in 2024, driven by the increasing demand for advanced diagnostic tools and efficient workflow solutions.
North America held the largest market share of 45.7% in 2024. This can be attributed to the regions developed healthcare infrastructure and increasing access to the computational pathology solutions coupled with the rising incidents of the chronic diseases such as cancer.
Grand View Research has segmented the global computational pathology market report based on component, application, technology, end use, and region:
Computational Pathology Component Outlook (Revenue, USD Million, 2021–2033)
Software
Services
Computational Pathology Application Outlook (Revenue, USD Million, 2021–2033)
Disease Diagnosis
Drug Discovery & Development
Academic Research
Computational Pathology Technology Outlook (Revenue, USD Million, 2021–2033)
Machine Learning (ML)
Deep Learning
Supervised
Unsupervised
Others
Natural Language Processing (NLP) Models
Computer Vision
Others
Computational Pathology End Use Outlook (Revenue, USD Million, 2021–2033)
Hospitals & Diagnostic Labs
Biotechnology & Pharmaceutical Companies
Academic & Research Institutes
Other
List of Key Players in Computational Pathology Market
Leica Biosystems Nussloch GmbH (subsidiary of Danaher)
Hamamatsu Photonics K.K.
Koninklijke Philips N.V.
Olympus Corporation
F. Hoffmann-La Roche Ltd.
Aiforia/ Aiforia Technologies PLC
Epredia (3DHISTECH Ltd.)
Visiopharm A/S
Proscia Inc.
Mindpeak GmbH
Akoya Biosciences, Inc. (a Quanterix company)
Paige AI, Inc.
CellaVision
aetherAI
Qritive
IBEX (IBEX MEDICAL ANALYTICS) Nucleai, Inc.
Nucleai, Inc.